TN2009000400A1 - Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha - Google Patents

Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha

Info

Publication number: TN2009000400A1
Authority: TN; Tunisia
Prior art keywords: treating cancer; pyridopyrimidininone; inhibitors; methods; pi3k alpha
Prior art date: 2007-04-10

Application number

TNP2009000400A

Other languages

English (en)

Inventor

Peter Lamb

David Matthews

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-10

Filing date

2009-09-30

Publication date

2010-12-31

2009-09-30 Application filed by Exelixis Inc filed Critical Exelixis Inc

2010-12-31 Publication of TN2009000400A1 publication Critical patent/TN2009000400A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

TNP2009000400A 2007-04-10 2009-09-30 Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha TN2009000400A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92289907P	2007-04-10	2007-04-10
PCT/US2008/004573 WO2008124161A1 (fr)	2007-04-10	2008-04-09	Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone

Publications (1)

Publication Number	Publication Date
TN2009000400A1 true TN2009000400A1 (en)	2010-12-31

Family

ID=39627802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000400A TN2009000400A1 (en)	2007-04-10	2009-09-30	Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha

Country Status (32)

Country	Link
US (1)	US8513266B2 (fr)
EP (1)	EP2139484B9 (fr)
JP (3)	JP2010523670A (fr)
KR (1)	KR101626435B1 (fr)
CN (2)	CN102727498B (fr)
AU (1)	AU2008236562B2 (fr)
BR (1)	BRPI0810206A2 (fr)
CA (1)	CA2683641C (fr)
CO (1)	CO6251254A2 (fr)
CR (1)	CR11100A (fr)
DK (1)	DK2139484T3 (fr)
DO (1)	DOP2009000243A (fr)
EA (1)	EA020022B1 (fr)
EC (1)	ECSP099724A (fr)
ES (1)	ES2430614T3 (fr)
HK (1)	HK1139863A1 (fr)
HN (1)	HN2009003002A (fr)
HR (1)	HRP20130688T1 (fr)
IL (1)	IL201284A (fr)
MA (1)	MA31358B1 (fr)
ME (1)	ME00936B (fr)
MX (1)	MX2009010930A (fr)
MY (1)	MY150697A (fr)
NZ (1)	NZ580110A (fr)
PL (1)	PL2139484T3 (fr)
PT (1)	PT2139484E (fr)
RS (1)	RS52939B (fr)
SI (1)	SI2139484T1 (fr)
TN (1)	TN2009000400A1 (fr)
UA (1)	UA100979C2 (fr)
WO (1)	WO2008124161A1 (fr)
ZA (1)	ZA200906764B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200726767A (en) *	2005-07-04	2007-07-16	Astrazeneca Ab	Chemical compounds 2
GEP20115304B (en) *	2005-10-07	2011-10-10	Exelixis Inc	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
NZ566837A (en) *	2005-10-07	2011-09-30	Exelixis Inc	N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as PI3K inhibitors
CN104784695A (zh)	2006-08-16	2015-07-22	埃克塞利希斯股份有限公司	使用pi3k和mek调控剂的方法
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) *	2007-01-11	2011-04-24	استرازينيكا ايه بي	مشتقات بيريدوبيريميدين كمثبطات pde4
US8513266B2 (en)	2007-04-10	2013-08-20	Exelixis, Inc.	Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
US8481001B2 (en) *	2007-04-11	2013-07-09	Exelixis, Inc.	Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
JP5654990B2 (ja)	2008-08-20	2015-01-14	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
TWI409265B (zh)	2008-08-20	2013-09-21	Merck Sharp & Dohme	經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
CA2734487A1 (fr)	2008-08-20	2010-02-25	Southern Research Institute	Derives de pyridine et de pyrimidine a substitution ethylyle et leur utilisation dans le traitement d'infections virales
CA2734489C (fr) *	2008-08-20	2016-11-08	Southern Research Institute	Derives de pyridine et de pyrimidine substitues par ethenyle et leur utilisation dans le traitement d'infections virales
TW201139436A (en)	2010-02-09	2011-11-16	Exelixis Inc	Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
WO2012027536A1 (fr) *	2010-08-26	2012-03-01	Bristol-Myers Squibb Company	Combinaison d'anticorps anti-ctla4 avec des inhibiteurs de braf pour le traitement synergique de maladies prolifératives
TWI642670B (zh)	2010-09-14	2018-12-01	伊塞利克斯公司	Ｐｉ３ｋ-德爾塔抑制劑以及其應用和生產方法
WO2012065019A2 (fr)	2010-11-12	2012-05-18	Exelixis, Inc.	Inhibiteurs pyridopyrimidinone de p13k alpha
WO2012158960A2 (fr)	2011-05-17	2012-11-22	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Ligands du récepteur à la mélanocortine de type 1 et leurs procédés d'utilisation
TW201306842A (zh) *	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EP2736325B1 (fr) *	2011-07-28	2018-10-10	F.Hoffmann-La Roche Ag	Modèle de cancer du sein d'animal non humain knock-in pik3ca h1047r
WO2013056067A1 (fr) *	2011-10-13	2013-04-18	Exelixis, Inc.	Composés pour une utilisation dans le traitement de carcinome des cellules basales
CN104302294A (zh)	2011-11-01	2015-01-21	埃克塞利希斯股份有限公司	用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺
JP6126615B2 (ja) *	2011-11-11	2017-05-10	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
CA2860051A1 (fr)	2011-12-27	2013-07-04	Kadmon Corporation, Llc	Procedes de traitement d'un cancer du sein ne repondant pas au trastuzumab
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112014032346A2 (pt)	2012-06-26	2017-06-27	Del Mar Pharmaceuticals	métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US8980259B2 (en) *	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
RS58734B1 (sr)	2012-08-07	2019-06-28	Novartis Ag	Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor
AU2014251038A1 (en)	2013-04-08	2015-11-26	Dennis M. Brown	Therapeutic benefit of suboptimally administered chemical compounds
US9950194B2 (en)	2014-09-09	2018-04-24	Mevion Medical Systems, Inc.	Patient positioning system
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
JP7085985B2 (ja)	2016-03-04	2022-06-17	大鵬薬品工業株式会社	悪性腫瘍治療用製剤及び組成物
PE20190475A1 (es) *	2016-08-15	2019-04-04	Pfizer	Inhibidores de cdk2/4/6
JP7027699B2 (ja) *	2017-05-09	2022-03-02	住友ゴム工業株式会社	タイヤトレッドおよびタイヤ
SG11202007287XA (en)	2018-01-31	2020-08-28	Deciphera Pharmaceuticals Llc	Combination therapy for the treatment of mastocytosis
BR112020015581A2 (pt)	2018-01-31	2021-02-02	Deciphera Pharmaceuticals, Llc	terapia de combinação para o tratamento de tumores estromais gastrointestinais
MX2020009762A (es)	2018-03-19	2021-01-08	Taiho Pharmaceutical Co Ltd	Composicion farmaceutica que incluye alquil sulfato de sodio.
BR112022002609A2 (pt)	2019-08-12	2022-08-09	Deciphera Pharmaceuticals Llc	Métodos de tratamento de tumores estromais gastrointestinais
WO2021030405A1 (fr)	2019-08-12	2021-02-18	Deciphera Pharmaceuticals, Llc	Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
US20230056729A1 (en) *	2019-12-10	2023-02-23	The Trustees Of Indiana University	Replication protein a (rpa)-dna interaction inhibitors
KR20220123057A (ko)	2019-12-30	2022-09-05	데시페라 파마슈티칼스, 엘엘씨.	비정질 키나아제 억제제 제형 및 이의 사용 방법
CN118948773A (zh)	2019-12-30	2024-11-15	德西费拉制药有限责任公司	1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
KR102195221B1 (ko)	2019-12-31	2020-12-24	서울대학교산학협력단	포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) *	2020-04-15	2022-03-15	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	一种抗肿瘤药物组合物及其制剂和应用
AU2022389984A1 (en) *	2021-11-18	2024-06-13	Traws Pharma, Inc.	Methods and compositions for treating cancer
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7019002B2 (en)	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
EP2277867B1 (fr)	2002-07-15	2012-12-05	Symphony Evolution, Inc.	Composés, compositions pharmaceutiques les contenants et leur utilisation pour traiter le cancer
JP2007523151A (ja)	2004-02-18	2007-08-16	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
JP2007536370A (ja)	2004-05-04	2007-12-13	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	療法薬としてのピロリル置換ピリド［２，３−ｄ］ピリミジン−７−オンおよびその誘導体
JP5216958B2 (ja) *	2005-07-06	2013-06-19	株式会社三和技術総合研究所	漏洩電流検出装置及び漏洩電流検出方法
CA2624965A1 (fr)	2005-10-07	2007-04-19	Exelixis, Inc.	Inhibiteurs pyridopyrimidinone de pi3ka
NZ566837A (en)	2005-10-07	2011-09-30	Exelixis Inc	N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as PI3K inhibitors
GEP20115304B (en) *	2005-10-07	2011-10-10	Exelixis Inc	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
CN104784695A (zh)	2006-08-16	2015-07-22	埃克塞利希斯股份有限公司	使用pi3k和mek调控剂的方法
SI2074122T1 (sl) *	2006-09-15	2011-10-28	Pfizer Prod Inc	Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
US8513266B2 (en)	2007-04-10	2013-08-20	Exelixis, Inc.	Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
AU2008239655B2 (en)	2007-04-11	2013-06-20	Exelixis, Inc.	Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
ES2425068T3 (es)	2007-04-11	2013-10-11	Exelixis, Inc.	Compuestos de pirido[2,3-d]pirimidin-7-ona como inhibidores de PI3K-alfa para el tratamiento del cáncer
US8481001B2 (en)	2007-04-11	2013-07-09	Exelixis, Inc.	Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
US8101622B2 (en)	2008-09-30	2012-01-24	Exelixis, Inc.	Pyridopyrimidinone inhibitors of PI3Kα and mTOR

2008
- 2008-04-09 US US12/595,219 patent/US8513266B2/en active Active
- 2008-04-09 EP EP08742677.1A patent/EP2139484B9/fr active Active
- 2008-04-09 PL PL08742677T patent/PL2139484T3/pl unknown
- 2008-04-09 EA EA200970932A patent/EA020022B1/ru not_active IP Right Cessation
- 2008-04-09 JP JP2010503045A patent/JP2010523670A/ja active Pending
- 2008-04-09 ME MEP-2009-303A patent/ME00936B/fr unknown
- 2008-04-09 CN CN201210032620.4A patent/CN102727498B/zh not_active Expired - Fee Related
- 2008-04-09 MX MX2009010930A patent/MX2009010930A/es active IP Right Grant
- 2008-04-09 RS RS20130384A patent/RS52939B/en unknown
- 2008-04-09 CN CN200880018725A patent/CN101715345A/zh active Pending
- 2008-04-09 DK DK08742677.1T patent/DK2139484T3/da active
- 2008-04-09 UA UAA200911419A patent/UA100979C2/ru unknown
- 2008-04-09 WO PCT/US2008/004573 patent/WO2008124161A1/fr active Application Filing
- 2008-04-09 CA CA2683641A patent/CA2683641C/fr not_active Expired - Fee Related
- 2008-04-09 AU AU2008236562A patent/AU2008236562B2/en not_active Ceased
- 2008-04-09 PT PT87426771T patent/PT2139484E/pt unknown
- 2008-04-09 SI SI200831004T patent/SI2139484T1/sl unknown
- 2008-04-09 MY MYPI20094214 patent/MY150697A/en unknown
- 2008-04-09 ES ES08742677T patent/ES2430614T3/es active Active
- 2008-04-09 KR KR1020097023351A patent/KR101626435B1/ko not_active Expired - Fee Related
- 2008-04-09 BR BRPI0810206-6A2A patent/BRPI0810206A2/pt not_active IP Right Cessation
- 2008-04-09 NZ NZ580110A patent/NZ580110A/en not_active IP Right Cessation
2009
- 2009-09-29 ZA ZA200906764A patent/ZA200906764B/xx unknown
- 2009-09-30 TN TNP2009000400A patent/TN2009000400A1/fr unknown
- 2009-10-01 IL IL201284A patent/IL201284A/en active IP Right Grant
- 2009-10-09 DO DO2009000243A patent/DOP2009000243A/es unknown
- 2009-10-09 HN HN2009003002A patent/HN2009003002A/es unknown
- 2009-11-02 MA MA32318A patent/MA31358B1/fr unknown
- 2009-11-09 EC EC2009009724A patent/ECSP099724A/es unknown
- 2009-11-09 CO CO09126924A patent/CO6251254A2/es not_active Application Discontinuation
- 2009-11-09 CR CR11100A patent/CR11100A/es unknown
2010
- 2010-07-05 HK HK10106503.5A patent/HK1139863A1/xx not_active IP Right Cessation
2013
- 2013-07-22 HR HRP20130688AT patent/HRP20130688T1/hr unknown
- 2013-09-19 JP JP2013194611A patent/JP2014034576A/ja active Pending
2014
- 2014-03-24 JP JP2014059561A patent/JP2014139217A/ja active Pending

Also Published As

Publication number	Publication date
ES2430614T3 (es)	2013-11-21
MX2009010930A (es)	2010-01-20
NZ580110A (en)	2012-06-29
HN2009003002A (es)	2014-03-24
PL2139484T3 (pl)	2013-12-31
JP2014139217A (ja)	2014-07-31
DK2139484T3 (da)	2013-10-21
JP2014034576A (ja)	2014-02-24
WO2008124161A1 (fr)	2008-10-16
CA2683641C (fr)	2016-08-16
EP2139484B9 (fr)	2014-06-11
ZA200906764B (en)	2010-08-25
IL201284A (en)	2016-06-30
DOP2009000243A (es)	2010-10-31
US20100209420A1 (en)	2010-08-19
UA100979C2 (ru)	2013-02-25
ECSP099724A (es)	2010-03-31
BRPI0810206A2 (pt)	2014-10-21
EP2139484A1 (fr)	2010-01-06
CN102727498B (zh)	2016-08-03
CN101715345A (zh)	2010-05-26
CN102727498A (zh)	2012-10-17
CO6251254A2 (es)	2011-02-21
AU2008236562B2 (en)	2013-11-07
MA31358B1 (fr)	2010-05-03
HRP20130688T1 (en)	2013-09-30
SI2139484T1 (sl)	2013-10-30
EP2139484B8 (fr)	2013-08-21
CA2683641A1 (fr)	2008-10-16
EP2139484B1 (fr)	2013-07-17
AU2008236562A1 (en)	2008-10-16
PT2139484E (pt)	2013-10-31
JP2010523670A (ja)	2010-07-15
EA200970932A1 (ru)	2010-04-30
RS52939B (en)	2014-02-28
HK1139863A1 (en)	2010-09-30
KR20100016354A (ko)	2010-02-12
KR101626435B1 (ko)	2016-06-01
US8513266B2 (en)	2013-08-20
MY150697A (en)	2014-02-28
CR11100A (es)	2010-01-19
ME00936B (fr)	2012-06-20
EA020022B1 (ru)	2014-08-29
IL201284A0 (en)	2010-05-31

Publication	Publication Date	Title
TN2009000400A1 (en)	2010-12-31	Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
UA98141C2 (ru)	2012-04-25	Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TR201900306T4 (tr)	2019-02-21	Mek inhibitörlerini kullanma yöntemleri.
TW200738725A (en)	2007-10-16	Unsaturated mTOR inhibitors
MX2009009786A (es)	2009-09-24	Inhibidores de la via de hedgehog.
TN2012000622A1 (en)	2014-04-01	Combinations of kinase inhibitors for the treatment of cancer
MY146111A (en)	2012-06-29	Acylaminopyrazoles as fgfr inhibitors
JO2886B1 (en)	2015-03-15	Useful compounds in the inhibition of CHK1
NZ595572A (en)	2013-07-26	Inhibitors of pi3 kinase and / or mtor
TW200740776A (en)	2007-11-01	N-phenylbenzotriazolyl c-kit inhibitors
MX2010010300A (es)	2010-10-26	Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
TN2013000237A1 (en)	2014-11-10	Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
MX2008011633A (es)	2008-12-16	Aminoquinolonas como inhibidores de gsk-3.
HK1162502A1 (en)	2012-08-31	Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2010004967A (es)	2010-07-30	Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
UA96969C2 (en)	2011-12-26	Acylaminopyrazoles as fgfr inhibitors
JO3145B1 (ar)	2017-09-20	مركبات مفيدة لتثبيط chk1
IN2012DN02816A (fr)	2015-07-24
WO2010014798A3 (fr)	2010-05-14	Pyrimidotriazinediones et pyrimidopyrimidinediones et procédés d’utilisation
WO2007136615A3 (fr)	2008-07-24	Thérapie anticancéreuse combinée
UA99612C2 (en)	2012-09-10	Inhibitors of the hedgehog pathway
CY1114609T1 (el)	2016-10-05	Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη